static1.squarespace.png

Akagera Medicines is developing novel liposomal formulations of antibacterial drugs to treat tuberculosis. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, incorporated as a Delaware corporation, and has laboratories in Boston and San Francisco. Board members and advisors include Ambassador Dr. Albrecht Conze, Dr. Paul Farmer, Dr. Donald Kaberuka, and Dr. Anne Lenaerts. Akagera Medicines intends (if toxicology and Proof of Concept efficacy studies go as anticipated) to begin IND-enabling studies in Q4 2020.